| 2.7 0.01 (0.37%) | 04-23 15:45 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.44 | 1-year : | 4.02 |
| Resists | First : | 2.95 | Second : | 3.44 |
| Pivot price | 2.65  |
|||
| Supports | First : | 2.61 | Second : | 2.41 |
| MAs | MA(5) : | 2.62 |
MA(20) : | 2.69 |
| MA(100) : | 2.92 |
MA(250) : | 3.21 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 51 |
D(3) : | 42.3 |
| RSI | RSI(14): 49.3 |
|||
| 52-week | High : | 4.55 | Low : | 2.41 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LUMO ] has closed below upper band by 33.7%. Bollinger Bands are 2.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.68 - 2.7 | 2.7 - 2.71 |
| Low: | 2.57 - 2.58 | 2.58 - 2.6 |
| Close: | 2.66 - 2.68 | 2.68 - 2.7 |
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Mon, 22 Apr 2024
Reviewing Lumos Pharma (NASDAQ:LUMO) & Ainos (NASDAQ:AIMD) - Defense World
Thu, 07 Mar 2024
LUMO Stock Earnings: Lumos Pharma Misses EPS for Q4 2023 - InvestorPlace
Mon, 05 Feb 2024
Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Invest In Growth? - Yahoo Finance
Wed, 08 Nov 2023
Why American Public Education Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarke - Benzinga
Tue, 07 Nov 2023
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD ... - Yahoo Finance
Tue, 07 Nov 2023
Lumos stock rockets nearly 100% in after-hours trading on study updates (LUMO) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 5.3e+006 (%) |
| Held by Institutions | 34.8 (%) |
| Shares Short | 298 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.657e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 211.1 % |
| Return on Equity (ttm) | -40.6 % |
| Qtrly Rev. Growth | 2.05e+006 % |
| Gross Profit (p.s.) | 175.14 |
| Sales Per Share | -223.83 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -4.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.1 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.28 |
| Dividend | 0 |
| Forward Dividend | 287460 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|